{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:53Z","timestamp":1793282513253,"version":"4.5.0"},"reference-count":221,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41569-019-0164-7","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T16:05:10Z","timestamp":1550246710000},"page":"325-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword"],"prefix":"10.1038","volume":"16","author":[{"given":"Karin H.","family":"Simons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-8359","authenticated-orcid":false,"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-9130","authenticated-orcid":false,"given":"Margreet R.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Arens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-5760","authenticated-orcid":false,"given":"Paul H. A.","family":"Quax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"164_CR1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"164_CR2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3031","volume":"15","author":"JT Chang","year":"2014","unstructured":"Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15, 1104\u20131115 (2014).","journal-title":"Nat. Immunol."},{"key":"164_CR3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","volume":"169","author":"P Bretscher","year":"1970","unstructured":"Bretscher, P. & Cohn, M. A theory of self-nonself discrimination. Science 169, 1042\u20131049 (1970).","journal-title":"Science"},{"key":"164_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","volume":"53","author":"KJ Lafferty","year":"1975","unstructured":"Lafferty, K. J. & Cunningham, A. J. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53, 27\u201342 (1975).","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"164_CR5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0167-5699(00)01750-3","volume":"21","author":"GF Gao","year":"2000","unstructured":"Gao, G. F. & Jakobsen, B. K. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T cell receptor. Immunol. Today 21, 630\u2013636 (2000).","journal-title":"Immunol. Today"},{"key":"164_CR6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1471-4906(02)02282-2","volume":"23","author":"GF Gao","year":"2002","unstructured":"Gao, G. F., Rao, Z. & Bell, J. I. Molecular coordination of alphabeta T cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol. 23, 408\u2013413 (2002).","journal-title":"Trends Immunol."},{"key":"164_CR7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI0214941","volume":"109","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth, K. A. & Thompson, C. B. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109, 295\u2013299 (2002).","journal-title":"J. Clin. Invest."},{"key":"164_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher, M. F. et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211, 81\u201392 (2006).","journal-title":"Immunol. Rev."},{"key":"164_CR9","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1073\/pnas.1203543109","volume":"109","author":"BE Freeman","year":"2012","unstructured":"Freeman, B. E., Hammarlund, E., Raue, H. P. & Slifka, M. K. Regulation of innate CD8+\u2009T cell activation mediated by cytokines. Proc. Natl Acad. Sci.\u00a0USA 109, 9971\u20139976 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/369648a0","volume":"369","author":"LL Lau","year":"1994","unstructured":"Lau, L. L., Jamieson, B. D., Somasundaram, T. & Ahmed, R. Cytotoxic T cell memory without antigen. Nature 369, 648\u2013652 (1994).","journal-title":"Nature"},{"key":"164_CR11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/369652a0","volume":"369","author":"S Hou","year":"1994","unstructured":"Hou, S., Hyland, L., Ryan, K. W., Portner, A. & Doherty, P. C. Virus-specific CD8+\u2009T cell memory determined by clonal burst size. Nature 369, 652\u2013654 (1994).","journal-title":"Nature"},{"key":"164_CR12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/eji.200940017","volume":"40","author":"G Genova Di","year":"2010","unstructured":"Di Genova, G., Savelyeva, N., Suchacki, A., Thirdborough, S. M. & Stevenson, F. K. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. Eur. J. Immunol. 40, 976\u2013985 (2010).","journal-title":"Eur. J. Immunol."},{"key":"164_CR13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","volume":"14","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow, D. J., Walunas, T. L. & Bluestone, J. A. CD28\/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233\u2013258 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"164_CR14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0952-7915(97)80087-8","volume":"9","author":"CA Chambers","year":"1997","unstructured":"Chambers, C. A. & Allison, J. P. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9, 396\u2013404 (1997).","journal-title":"Curr. Opin. Immunol."},{"key":"164_CR15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/eji.201646500","volume":"46","author":"V Heide van der","year":"2016","unstructured":"van der Heide, V. & Homann, D. CD28 days later: resurrecting costimulation for CD8+ memory T cells. Eur. J. Immunol. 46, 1587\u20131591 (2016).","journal-title":"Eur. J. Immunol."},{"key":"164_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973\u2013988 (2016).","journal-title":"Immunity"},{"key":"164_CR17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"LK Ward-Kavanagh","year":"2016","unstructured":"Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R. & Ware, C. F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 44, 1005\u20131019 (2016).","journal-title":"Immunity"},{"key":"164_CR18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116\u2013126 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","volume":"23","author":"TH Watts","year":"2005","unstructured":"Watts, T. H. TNF\/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23\u201368 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"164_CR20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","volume":"44","author":"FA Schildberg","year":"2016","unstructured":"Schildberg, F. A., Klein, S. R., Freeman, G. J. & Sharpe, A. H. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44, 955\u2013972 (2016).","journal-title":"Immunity"},{"key":"164_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The\u00a0B7 family revisited. Annu. Rev. Immunol. 23, 515\u2013548 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"164_CR22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","volume":"276","author":"AH Sharpe","year":"2017","unstructured":"Sharpe, A. H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol. Rev. 276, 5\u20138 (2017).","journal-title":"Immunol. Rev."},{"key":"164_CR23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","volume":"44","author":"J Attanasio","year":"2016","unstructured":"Attanasio, J. & Wherry, E. J. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 44, 1052\u20131068 (2016).","journal-title":"Immunity"},{"key":"164_CR24","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.4049\/jimmunol.1100038","volume":"188","author":"PM Odorizzi","year":"2012","unstructured":"Odorizzi, P. M. & Wherry, E. J. Inhibitory receptors on lymphocytes: insights from infections. J. Immunol. 188, 2957\u20132965 (2012).","journal-title":"J. Immunol."},{"key":"164_CR25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"164_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"164_CR29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","volume":"65","author":"DB Page","year":"2014","unstructured":"Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185\u2013202 (2014).","journal-title":"Annu. Rev. Med."},{"key":"164_CR30","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","volume":"25","author":"G Varricchi","year":"2018","unstructured":"Varricchi, G. et al. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr. Med. Chem. 25, 1327\u20131339 (2018).","journal-title":"Curr. Med. Chem."},{"key":"164_CR31","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"164_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer, L. et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 210\u2013225 (2016).","journal-title":"Eur. J. Cancer"},{"key":"164_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.coi.2005.04.004","volume":"17","author":"J Borst","year":"2005","unstructured":"Borst, J., Hendriks, J. & Xiao, Y. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17, 275\u2013281 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"164_CR34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4049\/jimmunol.170.1.33","volume":"170","author":"K Tesselaar","year":"2003","unstructured":"Tesselaar, K. et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170, 33\u201340 (2003).","journal-title":"J. Immunol."},{"key":"164_CR35","doi-asserted-by":"crossref","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","volume":"271","author":"JA Greene","year":"1996","unstructured":"Greene, J. A. et al. Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271, 26762\u201326771 (1996).","journal-title":"J. Biol. Chem."},{"key":"164_CR36","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/cvr\/cvy060.145","volume":"114","author":"KH Simons","year":"2018","unstructured":"Simons, K. H. et al. Co-stimulation dependent CD8 T cell activation protects vein graft disease. Cardiovasc. Res. 114, S50 (2018).","journal-title":"Cardiovasc. Res."},{"key":"164_CR37","doi-asserted-by":"crossref","first-page":"1800018","DOI":"10.3389\/fphys.2012.00018","volume":"3","author":"AH Lichtman","year":"2012","unstructured":"Lichtman, A. H. T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Front. Physiol. 3, 1800018 (2012).","journal-title":"Front. Physiol."},{"key":"164_CR38","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.RES.0000261982.76892.09","volume":"100","author":"RN Mitchell","year":"2007","unstructured":"Mitchell, R. N. & Libby, P. Vascular remodeling in transplant vasculopathy. Circ. Res. 100, 967\u2013978 (2007).","journal-title":"Circ. Res."},{"key":"164_CR39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","volume":"5","author":"Y Li","year":"1999","unstructured":"Li, Y. et al. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5, 1298\u20131302 (1999).","journal-title":"Nat. Med."},{"key":"164_CR40","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/15260","volume":"5","author":"AD Wells","year":"1999","unstructured":"Wells, A. D. et al. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5, 1303\u20131307 (1999).","journal-title":"Nat. Med."},{"key":"164_CR41","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4049\/jimmunol.175.3.1575","volume":"175","author":"A Jansson","year":"2005","unstructured":"Jansson, A. et al. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J. Immunol. 175, 1575\u20131585 (2005).","journal-title":"J. Immunol."},{"key":"164_CR42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI118483","volume":"97","author":"ME Russell","year":"1996","unstructured":"Russell, M. E. et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97, 833\u2013838 (1996).","journal-title":"J. Clin. Invest."},{"key":"164_CR43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0002-9440(10)64044-8","volume":"158","author":"KS Kim","year":"2001","unstructured":"Kim, K. S. et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977\u2013986 (2001).","journal-title":"Am. J. Pathol."},{"key":"164_CR44","doi-asserted-by":"crossref","first-page":"13967","DOI":"10.1073\/pnas.93.24.13967","volume":"93","author":"WW Hancock","year":"1996","unstructured":"Hancock, W. W. et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl Acad. Sci. USA 93, 13967\u201313972 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0002-9440(10)64559-2","volume":"157","author":"Y Furukawa","year":"2000","unstructured":"Furukawa, Y., Mandelbrot, D. A., Libby, P., Sharpe, A. H. & Mitchell, R. N. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1\/B7-2. Am. J. Pathol. 157, 473\u2013484 (2000).","journal-title":"Am. J. Pathol."},{"key":"164_CR46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14680","volume":"8","author":"M Kallikourdis","year":"2017","unstructured":"Kallikourdis, M. et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat. Commun. 8, 14680 (2017).","journal-title":"Nat. Commun."},{"key":"164_CR47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0021-9150(97)00135-4","volume":"133","author":"OJ Boer de","year":"1997","unstructured":"de Boer, O. J. et al. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 133, 227\u2013234 (1997).","journal-title":"Atherosclerosis"},{"key":"164_CR48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.yexmp.2003.12.001","volume":"76","author":"A Afek","year":"2004","unstructured":"Afek, A., Harats, D., Roth, A., Keren, G. & George, J. Evidence for the involvement of T cell costimulation through the B-7\/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice. Exp. Mol. Pathol. 76, 219\u2013223 (2004).","journal-title":"Exp. Mol. Pathol."},{"key":"164_CR49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MCA.0b013e3282eff1ad","volume":"18","author":"JF Dopheide","year":"2007","unstructured":"Dopheide, J. F. et al. Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron. Artery Dis. 18, 523\u2013531 (2007).","journal-title":"Coron. Artery Dis."},{"key":"164_CR50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijcard.2014.04.071","volume":"174","author":"A Muller","year":"2014","unstructured":"Muller, A. et al. Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. Int. J. Cardiol. 174, 503\u2013515 (2014).","journal-title":"Int. J. Cardiol."},{"key":"164_CR51","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1161\/CIRCRESAHA.108.182428","volume":"103","author":"I Gotsman","year":"2008","unstructured":"Gotsman, I., Sharpe, A. H. & Lichtman, A. H. T cell costimulation and coinhibition in atherosclerosis. Circ. Res. 103, 1220\u20131231 (2008).","journal-title":"Circ. Res."},{"key":"164_CR52","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1161\/01.CIR.0000127121.16815.F1","volume":"109","author":"C Buono","year":"2004","unstructured":"Buono, C. et al. B7-1\/B7-2 costimulation regulates plaque antigen-specific T cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 109, 2009\u20132015 (2004).","journal-title":"Circulation"},{"key":"164_CR53","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","volume":"168","author":"MM Ewing","year":"2013","unstructured":"Ewing, M. M. et al. T cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int. J. Cardiol. 168, 1965\u20131974 (2013).","journal-title":"Int. J. Cardiol."},{"key":"164_CR54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","volume":"97","author":"K Ma","year":"2013","unstructured":"Ma, K. et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T cell overactivation in apoE\u2212\/\u2212 mice. Cardiovasc. Res. 97, 349\u2013359 (2013).","journal-title":"Cardiovasc. Res."},{"key":"164_CR55","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","volume":"36","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto, T. et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 36, 1141\u20131151 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","volume":"12","author":"H Ait-Oufella","year":"2006","unstructured":"Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178\u2013180 (2006).","journal-title":"Nat. Med."},{"key":"164_CR57","first-page":"804","volume":"106","author":"N Gerdes","year":"2011","unstructured":"Gerdes, N. & Zirlik, A. Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis? Thromb. Haemostat. 106, 804\u2013813 (2011).","journal-title":"Haemostat."},{"key":"164_CR58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303\u2013310 (2000).","journal-title":"J. Exp. Med."},{"key":"164_CR59","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1073\/pnas.88.15.6575","volume":"88","author":"CD Gimmi","year":"1991","unstructured":"Gimmi, C. D. et al. B cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl Acad. Sci. USA 88, 6575\u20136579 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR60","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.180.6.2049","volume":"180","author":"RJ Peach","year":"1994","unstructured":"Peach, R. J. et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180, 2049\u20132058 (1994).","journal-title":"J. Exp. Med."},{"key":"164_CR61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"164_CR62","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20070657","volume":"204","author":"TJ Guzik","year":"2007","unstructured":"Guzik, T. J. et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204, 2449\u20132460 (2007).","journal-title":"J. Exp. Med."},{"key":"164_CR63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111\u2013122 (2007).","journal-title":"Immunity"},{"key":"164_CR64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319\u2013322 (2001).","journal-title":"Science"},{"key":"164_CR65","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477\u20131483 (2003).","journal-title":"Nat. Med."},{"key":"164_CR66","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio, M. L., Grabie, N., Bu, D. X., Sharpe, A. H. & Lichtman, A. H. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 188, 4876\u20134884 (2012).","journal-title":"J. Immunol."},{"key":"164_CR67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang, J. et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22, 443\u2013452 (2010).","journal-title":"Int. Immunol."},{"key":"164_CR68","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas, J. A. et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181, 2513\u20132521 (2008).","journal-title":"J. Immunol."},{"key":"164_CR69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4049\/jimmunol.1701076","volume":"200","author":"KW Juchem","year":"2018","unstructured":"Juchem, K. W. et al. PD-L1 prevents the development of autoimmune heart disease in graft-versus-host disease. J. Immunol. 200, 834\u2013846 (2018).","journal-title":"J. Immunol."},{"key":"164_CR70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093280","volume":"9","author":"C Cochain","year":"2014","unstructured":"Cochain, C. et al. Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLOS ONE 9, e93280 (2014).","journal-title":"PLOS ONE"},{"key":"164_CR71","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"DX Bu","year":"2011","unstructured":"Bu, D. X. et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1100\u20131107 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR72","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman, I. et al. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J. Clin. Invest. 117, 2974\u20132982 (2007).","journal-title":"J. Clin. Invest."},{"key":"164_CR73","doi-asserted-by":"crossref","first-page":"0031","DOI":"10.1038\/s41551-017-0031","volume":"1","author":"M Mahmoudi","year":"2017","unstructured":"Mahmoudi, M. & Farokhzad, O. C. Cancer immunotherapy: wound-bound checkpoint blockade. Nat. Biomed. Eng. 1, 0031 (2017).","journal-title":"Nat. Biomed. Eng."},{"key":"164_CR74","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561\u2013584 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"164_CR75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2016.00304","volume":"7","author":"DJ Wikenheiser","year":"2016","unstructured":"Wikenheiser, D. J. & Stumhofer, J. S. ICOS co-stimulation: friend or foe? Front. Immunol. 7, 304 (2016).","journal-title":"Front. Immunol."},{"key":"164_CR76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2005.03.040","volume":"183","author":"A Afek","year":"2005","unstructured":"Afek, A., Harats, D., Roth, A., Keren, G. & George, J. A functional role for inducible costimulator (ICOS) in atherosclerosis. Atherosclerosis 183, 57\u201363 (2005).","journal-title":"Atherosclerosis"},{"key":"164_CR77","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.106.633263","volume":"114","author":"I Gotsman","year":"2006","unstructured":"Gotsman, I. et al. Impaired regulatory T cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114, 2047\u20132055 (2006).","journal-title":"Circulation"},{"key":"164_CR78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coi.2010.01.001","volume":"22","author":"TR Simpson","year":"2010","unstructured":"Simpson, T. R., Quezada, S. A. & Allison, J. P. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 22, 326\u2013332 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"164_CR79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14728222.2018.1444753","volume":"22","author":"F Amatore","year":"2018","unstructured":"Amatore, F., Gorvel, L. & Olive, D. Inducible co-stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin. Ther. Targets 22, 343\u2013351 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"164_CR80","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.4049\/jimmunol.0902937","volume":"184","author":"LP Kane","year":"2010","unstructured":"Kane, L. P. T cell Ig and mucin domain proteins and immunity. J. Immunol. 184, 2743\u20132749 (2010).","journal-title":"J. Immunol."},{"key":"164_CR81","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri1111","volume":"3","author":"VK Kuchroo","year":"2003","unstructured":"Kuchroo, V. K., Umetsu, D. T., DeKruyff, R. H. & Freeman, G. J. The TIM gene family: emerging roles in immunity and disease. Nat. Rev. Immunol. 3, 454\u2013462 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR82","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.4049\/jimmunol.178.11.6710","volume":"178","author":"S Frisancho-Kiss","year":"2007","unstructured":"Frisancho-Kiss, S. et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol. 178, 6710\u20136714 (2007).","journal-title":"J. Immunol."},{"key":"164_CR83","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1536\/ihj.16-119","volume":"57","author":"X Xie","year":"2016","unstructured":"Xie, X., Li, C., Zhou, B., Dai, X. & Rao, L. Associations between TIM1 polymorphisms and dilated cardiomyopathy in a Han Chinese population. Int. Heart J. 57, 742\u2013746 (2016).","journal-title":"Int. Heart J."},{"key":"164_CR84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2015.07.023","volume":"242","author":"L Lind","year":"2015","unstructured":"Lind, L. et al. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 242, 205\u2013210 (2015).","journal-title":"Atherosclerosis"},{"key":"164_CR85","doi-asserted-by":"crossref","first-page":"BSR20171058","DOI":"10.1042\/BSR20171058","volume":"38","author":"QH Zhang","year":"2018","unstructured":"Zhang, Q. H., Yin, R. X., Chen, W. X., Cao, X. L. & Chen, Y. M. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Biosci. Rep. 38, BSR20171058 (2018).","journal-title":"Biosci. Rep."},{"key":"164_CR86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/ATVBAHA.115.306860","volume":"36","author":"AC Foks","year":"2016","unstructured":"Foks, A. C. et al. Blockade of Tim-1 and Tim-4 enhances atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 36, 456\u2013465 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR87","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.4049\/jimmunol.176.11.6411","volume":"176","author":"SN Frisancho-Kiss","year":"2006","unstructured":"Frisancho-Kiss, S. N. et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J. Immunol. 176, 6411\u20136415 (2006).","journal-title":"J. Immunol."},{"key":"164_CR88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nri2456","volume":"9","author":"PL Schwartzberg","year":"2009","unstructured":"Schwartzberg, P. L., Mueller, K. L., Qi, H. & Cannons, J. L. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol. 9, 39\u201346 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR89","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.ATV.0000229695.68416.76","volume":"26","author":"M Papaspyridonos","year":"2006","unstructured":"Papaspyridonos, M. et al. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 26, 1837\u20131844 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033787","volume":"7","author":"M Levula","year":"2012","unstructured":"Levula, M. et al. Genes involved in systemic and arterial bed dependent atherosclerosis\u2014Tampere Vascular study. PLOS ONE 7, e33787 (2012).","journal-title":"PLOS ONE"},{"key":"164_CR91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.it.2011.09.007","volume":"33","author":"L Abeler-Dorner","year":"2012","unstructured":"Abeler-Dorner, L., Swamy, M., Williams, G., Hayday, A. C. & Bas, A. Butyrophilins: an emerging family of immune regulators. Trends Immunol. 33, 34\u201341 (2012).","journal-title":"Trends Immunol."},{"key":"164_CR92","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.4049\/jimmunol.1201760","volume":"190","author":"RM Swanson","year":"2013","unstructured":"Swanson, R. M. et al. Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells. J. Immunol. 190, 2027\u20132035 (2013).","journal-title":"J. Immunol."},{"key":"164_CR93","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.4049\/jimmunol.1000835","volume":"185","author":"T Yamazaki","year":"2010","unstructured":"Yamazaki, T. et al. A butyrophilin family member critically inhibits T cell activation. J. Immunol. 185, 5907\u20135914 (2010).","journal-title":"J. Immunol."},{"key":"164_CR94","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cyto.2009.03.009","volume":"46","author":"HA Arnett","year":"2009","unstructured":"Arnett, H. A., Escobar, S. S. & Viney, J. L. Regulation of costimulation in the era of butyrophilins. Cytokine 46, 370\u2013375 (2009).","journal-title":"Cytokine"},{"key":"164_CR95","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","volume":"1843","author":"MD Turner","year":"2014","unstructured":"Turner, M. D., Nedjai, B., Hurst, T. & Pennington, D. J. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta 1843, 2563\u20132582 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"164_CR96","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nri1462","volume":"4","author":"GA Bishop","year":"2004","unstructured":"Bishop, G. A. The multifaceted roles of TRAFs in the regulation of B cell function. Nat. Rev. Immunol. 4, 775\u2013786 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"164_CR97","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"DG Song","year":"2012","unstructured":"Song, D. G. et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119, 696\u2013706 (2012).","journal-title":"Blood"},{"key":"164_CR98","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.thromres.2006.12.005","volume":"120","author":"G Sardella","year":"2007","unstructured":"Sardella, G. et al. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. Thromb. Res. 120, 631\u2013634 (2007).","journal-title":"Thromb. Res."},{"key":"164_CR99","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1160\/TH16-04-0318","volume":"117","author":"H Winkels","year":"2017","unstructured":"Winkels, H. et al. CD70 limits atherosclerosis and promotes macrophage function. Thromb. Haemostat. 117, 164\u2013175 (2017).","journal-title":"Thromb. Haemostat."},{"key":"164_CR100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000314772","volume":"2","author":"RW Olffen van","year":"2010","unstructured":"van Olffen, R. W. et al. CD70-driven chronic immune activation is protective against atherosclerosis. J. Innate Immun. 2, 344\u2013352 (2010).","journal-title":"J. Innate Immun."},{"key":"164_CR101","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2018.02.015","volume":"260","author":"KH Simons","year":"2018","unstructured":"Simons, K. H. et al. The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis. Int. J. Cardiol. 260, 184\u2013190 (2018).","journal-title":"Int. J. Cardiol."},{"key":"164_CR102","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","volume":"23","author":"P Aftimos","year":"2017","unstructured":"Aftimos, P. et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. Clin. Cancer Res. 23, 6411\u20136420 (2017).","journal-title":"Clin. Cancer Res."},{"key":"164_CR103","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","volume":"73","author":"BD Curti","year":"2013","unstructured":"Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189\u20137198 (2013).","journal-title":"Cancer Res."},{"key":"164_CR104","volume":"96","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. Clinical significance of costimulatory molecules CD40\/CD40L and CD134\/CD134L in coronary heart disease: a case-control study. Medicine 96, e7634 (2017).","journal-title":"Medicine"},{"key":"164_CR105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/147323001103900415","volume":"39","author":"JZ Shi","year":"2011","unstructured":"Shi, J. Z. et al. OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina. J. Int. Med. Res. 39, 1275\u20131283 (2011).","journal-title":"J. Int. Med. Res."},{"key":"164_CR106","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.cca.2010.06.016","volume":"411","author":"J Yan","year":"2010","unstructured":"Yan, J. et al. Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients. Clin. Chim. Acta 411, 1662\u20131665 (2010).","journal-title":"Clin. Chim. Acta"},{"key":"164_CR107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/FJC.0b013e3181be7578","volume":"54","author":"J Yan","year":"2009","unstructured":"Yan, J., Chen, G., Gong, J., Wang, C. & Du, R. Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes. J. Cardiovasc. Pharmacol. 54, 451\u2013455 (2009).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"164_CR108","first-page":"7","volume":"21","author":"A Kotani","year":"2002","unstructured":"Kotani, A., Hori, T., Matsumuru, Y. & Uchiyama, T. Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES\/CCL5. Immunol. Lett. 21, 7 (2002).","journal-title":"Immunol. Lett."},{"key":"164_CR109","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/CIRCRESAHA.111.261933","volume":"110","author":"IE Dumitriu","year":"2012","unstructured":"Dumitriu, I. E. et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ.\u00a0Res. 110, 857\u2013869 (2012).","journal-title":"Circ. Res."},{"key":"164_CR110","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1042\/CS20160074","volume":"130","author":"QQ Wu","year":"2016","unstructured":"Wu, Q. Q. et al. OX40 regulates pressure overload-induced cardiac hypertrophy and remodelling via CD4+ T cells. Clin. Sci. 130, 2061\u20132071 (2016).","journal-title":"Clin. Sci."},{"key":"164_CR111","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.4049\/jimmunol.1200708","volume":"191","author":"AC Foks","year":"2013","unstructured":"Foks, A. C. et al. Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. J. Immunol. 191, 4573\u20134580 (2013).","journal-title":"J. Immunol."},{"key":"164_CR112","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/01.CIR.0000143233.87854.23","volume":"110","author":"PR Moreno","year":"2004","unstructured":"Moreno, P. R. et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110, 2032\u20132038 (2004).","journal-title":"Circulation"},{"key":"164_CR113","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.ATV.0000187470.31662.fe","volume":"25","author":"MP Moos","year":"2005","unstructured":"Moos, M. P. et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 2386\u20132391 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2017.04.028","volume":"816","author":"L Parma","year":"2017","unstructured":"Parma, L., Baganha, F., Quax, P. H. A. & de Vries, M. R. Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur. J. Pharmacol. 816, 107\u2013115 (2017).","journal-title":"Eur. J. Pharmacol."},{"key":"164_CR115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MOL.0000000000000339","volume":"27","author":"MR Vries de","year":"2016","unstructured":"de Vries, M. R. & Quax, P. H. Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization. Curr. Opin. Lipidol. 27, 499\u2013506 (2016).","journal-title":"Curr. Opin. Lipidol."},{"key":"164_CR116","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cvr\/cvq211","volume":"88","author":"M Nakano","year":"2010","unstructured":"Nakano, M. et al. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc. Res. 88, 539\u2013546 (2010).","journal-title":"Cardiovasc. Res."},{"key":"164_CR117","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.transproceed.2013.03.038","volume":"45","author":"YL Wang","year":"2013","unstructured":"Wang, Y. L., Li, G., Fu, Y. X., Wang, H. & Shen, Z. Y. Blockade of OX40\/OX40 ligand to decrease cytokine messenger RNA expression in acute renal allograft rejection in vitro. Transplant. Proc. 45, 2565\u20132568 (2013).","journal-title":"Transplant. Proc."},{"key":"164_CR118","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaut.2011.01.006","volume":"36","author":"G Fousteri","year":"2011","unstructured":"Fousteri, G. et al. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J. Autoimmun. 36, 210\u2013220 (2011).","journal-title":"J. Autoimmun."},{"key":"164_CR119","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.ATV.0000251007.07648.81","volume":"27","author":"EJ Wanrooij van","year":"2007","unstructured":"van Wanrooij, E. J. et al. Interruption of the Tnfrsf4\/Tnfsf4 (OX40\/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 204\u2013210 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.bmt.1705587","volume":"39","author":"A Kotani","year":"2007","unstructured":"Kotani, A. et al. Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 39, 373\u2013375 (2007).","journal-title":"Bone Marrow Transplant."},{"key":"164_CR121","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00296-008-0697-2","volume":"29","author":"YB Zhou","year":"2009","unstructured":"Zhou, Y. B., Ye, R. G., Li, Y. J. & Xie, C. M. Targeting the CD134-CD134L interaction using anti-CD134 and\/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol. Int. 29, 417\u2013425 (2009).","journal-title":"Rheumatol. Int."},{"key":"164_CR122","doi-asserted-by":"crossref","first-page":"TPS3107","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3107","volume":"34","author":"JR Infante","year":"2016","unstructured":"Infante, J. R. et al. ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors. J. Clin. Oncol. 34, TPS3107 (2016).","journal-title":"J. Clin. Oncol."},{"key":"164_CR123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5483\/BMBRep.2014.47.3.283","volume":"47","author":"DS Vinay","year":"2014","unstructured":"Vinay, D. S. & Kwon, B. S. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 47, 122\u2013129 (2014).","journal-title":"BMB Rep."},{"key":"164_CR124","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cca.2009.12.011","volume":"411","author":"L Dongming","year":"2010","unstructured":"Dongming, L., Zuxun, L., Liangjie, X., Biao, W. & Ping, Y. Enhanced levels of soluble and membrane-bound CD137 levels in patients with acute coronary syndromes. Clin. Chim. Acta 411, 406\u2013410 (2010).","journal-title":"Clin. Chim. Acta"},{"key":"164_CR125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.6061\/clinics\/2013(02)OA12","volume":"68","author":"J Yan","year":"2013","unstructured":"Yan, J., Wang, C., Chen, R. & Yang, H. Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome. Clinics 68, 193\u2013198 (2013).","journal-title":"Clinics"},{"key":"164_CR126","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jacc.2012.06.034","volume":"60","author":"D Baldassarre","year":"2012","unstructured":"Baldassarre, D. et al. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. J. Am. Coll. Cardiol. 60, 1489\u20131499 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"164_CR127","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2119\/molmed.2014.00004","volume":"20","author":"LA Soderstrom","year":"2014","unstructured":"Soderstrom, L. A. et al. Human genetic evidence for involvement of CD137 in atherosclerosis. Mol. Med. 20, 456\u2013465 (2014).","journal-title":"Mol. Med."},{"key":"164_CR128","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1161\/CIRCULATIONAHA.107.699173","volume":"117","author":"PS Olofsson","year":"2008","unstructured":"Olofsson, P. S. et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117, 1292\u20131301 (2008).","journal-title":"Circulation"},{"key":"164_CR129","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCULATIONAHA.109.882704","volume":"121","author":"HJ Jeon","year":"2010","unstructured":"Jeon, H. J. et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 121, 1124\u20131133 (2010).","journal-title":"Circulation"},{"key":"164_CR130","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","volume":"24","author":"NH Segal","year":"2018","unstructured":"Segal, N. H. et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer. Clin. Cancer Res. 24, 1816\u20131823 (2018).","journal-title":"Clin. Cancer Res."},{"key":"164_CR131","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2008.26.15_suppl.3007","volume":"26","author":"M Sznol","year":"2008","unstructured":"Sznol, M. et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol. 26, 3007\u20133007 (2008).","journal-title":"J. Clin. Oncol."},{"key":"164_CR132","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-15-0263","volume":"21","author":"A Yonezawa","year":"2015","unstructured":"Yonezawa, A., Dutt, S., Chester, C., Kim, J. & Kohrt, H. E. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin. Cancer Res. 21, 3113\u20133120 (2015).","journal-title":"Clin. Cancer Res."},{"key":"164_CR133","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","volume":"23","author":"AW Tolcher","year":"2017","unstructured":"Tolcher, A. W. et al. Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin. Cancer Res. 23, 5349\u20135357 (2017).","journal-title":"Clin. Cancer Res."},{"key":"164_CR134","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.153.7.2861","volume":"153","author":"M Alzona","year":"1994","unstructured":"Alzona, M., J\u00e4ck, H. R., Fisher, R. I. & Ellis, T. M. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J. Immunol. 153, 6 (1994).","journal-title":"J. Immunol."},{"key":"164_CR135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1054-8807(02)00101-1","volume":"11","author":"Y Seko","year":"2002","unstructured":"Seko, Y. et al. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. Cardiovasc. Pathol. 11, 166\u2013170 (2002).","journal-title":"Cardiovasc. Pathol."},{"key":"164_CR136","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1161\/ATVBAHA.112.300509","volume":"32","author":"AC Foks","year":"2012","unstructured":"Foks, A. C. et al. Interference of the CD30-CD30L pathway reduces atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 32, 2862\u20132868 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR137","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1111\/bph.13802","volume":"174","author":"AC Foks","year":"2017","unstructured":"Foks, A. C. & Kuiper, J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol. 174, 3940\u20133955 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"164_CR138","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molimm.2007.05.013","volume":"45","author":"EM Bae","year":"2008","unstructured":"Bae, E. M. et al. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Mol. Immunol. 45, 523\u2013533 (2008).","journal-title":"Mol. Immunol."},{"key":"164_CR139","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/ATVBAHA.116.307354","volume":"36","author":"S Meiler","year":"2016","unstructured":"Meiler, S. et al. Constitutive GITR activation reduces atherosclerosis by promoting regulatory CD4+\u2009T-cell responses: brief report. Arterioscler. Thromb. Vasc. Biol. 36, 1748\u20131752 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR140","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/cdd.2011.145","volume":"19","author":"M Takata","year":"2012","unstructured":"Takata, M. et al. Glucocorticoid-induced TNF receptor-triggered T cells are key modulators for survival\/death of neural stem\/progenitor cells induced by ischemic stroke. Cell Death Differ. 19, 756\u2013767 (2012).","journal-title":"Cell Death Differ."},{"key":"164_CR141","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.4049\/jimmunol.176.8.4748","volume":"176","author":"M Ono","year":"2006","unstructured":"Ono, M., Shimizu, J., Miyachi, Y. & Sakaguchi, S. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related proteinhigh, Foxp3-expressing CD25+ and CD25\u2212 regulatory T cells. J. Immunol. 176, 4748\u20134756 (2006).","journal-title":"J. Immunol."},{"key":"164_CR142","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2010-01-261206","volume":"116","author":"D Lievens","year":"2010","unstructured":"Lievens, D. et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 116, 4317\u20134327 (2010).","journal-title":"Blood"},{"key":"164_CR143","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","volume":"21","author":"DY Ma","year":"2009","unstructured":"Ma, D. Y. & Clark, E. A. The role of CD40 and CD154\/CD40L in dendritic cells. Semin. Immunol. 21, 265\u2013272 (2009).","journal-title":"Semin. Immunol."},{"key":"164_CR144","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.CIR.100.6.614","volume":"100","author":"P Aukrust","year":"1999","unstructured":"Aukrust, P. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100, 614\u2013620 (1999).","journal-title":"Circulation"},{"key":"164_CR145","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.STR.0000074032.64049.47","volume":"34","author":"CD Garlichs","year":"2003","unstructured":"Garlichs, C. D. et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34, 1412\u20131418 (2003).","journal-title":"Stroke"},{"key":"164_CR146","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1073\/pnas.97.13.7464","volume":"97","author":"E Lutgens","year":"2000","unstructured":"Lutgens, E. et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc. Natl Acad. Sci. USA 97, 5 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR147","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.94.5.1931","volume":"94","author":"F Mach","year":"1997","unstructured":"Mach, F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl Acad. Sci. USA 94, 1931\u20131936 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR148","first-page":"6","volume":"91","author":"U Sch\u00f6nbeck","year":"1997","unstructured":"Sch\u00f6nbeck, U. et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. 91, 6 (1997).","journal-title":"Circ. Res."},{"key":"164_CR149","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20091293","volume":"207","author":"E Lutgens","year":"2010","unstructured":"Lutgens, E. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391\u2013404 (2010).","journal-title":"J. Exp. Med."},{"key":"164_CR150","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1073\/pnas.94.16.8789","volume":"94","author":"AD Kirk","year":"1997","unstructured":"Kirk, A. D. et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94, 8789\u20138794 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR151","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/9536","volume":"5","author":"AD Kirk","year":"1999","unstructured":"Kirk, A. D. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5, 686\u2013693 (1999).","journal-title":"Nat. Med."},{"key":"164_CR152","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","volume":"71","author":"TTP Seijkens","year":"2018","unstructured":"Seijkens, T. T. P. et al. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. J. Am. Coll. Cardiol. 71, 527\u2013542 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"164_CR153","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41551-018-0221-2","volume":"2","author":"M Lameijer","year":"2018","unstructured":"Lameijer, M. et al. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat. Biomed. Eng. 2, 279\u2013292 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"164_CR154","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ijo.2014.198","volume":"39","author":"SM Berg van den","year":"2015","unstructured":"van den Berg, S. M. et al. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. Int. J. Obes. 39, 782\u2013790 (2015).","journal-title":"Int. J. Obes."},{"key":"164_CR155","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1073\/pnas.1400419111","volume":"111","author":"A Chatzigeorgiou","year":"2014","unstructured":"Chatzigeorgiou, A. et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc. Natl Acad. Sci. USA 111, 2686\u20132691 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR156","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/ci500631e","volume":"55","author":"B Zarzycka","year":"2015","unstructured":"Zarzycka, B. et al. Discovery of small molecule CD40-TRAF6 inhibitors. J. Chem. Inf. Model. 55, 294\u2013307 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"164_CR157","first-page":"13","volume":"16","author":"T Migone","year":"2002","unstructured":"Migone, T. et al. TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator. Cell 16, 13 (2002).","journal-title":"Cell"},{"key":"164_CR158","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1084\/jem.20072528","volume":"205","author":"L Fang","year":"2008","unstructured":"Fang, L., Adkins, B., Deyev, V. & Podack, E. R. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J. Exp. Med. 205, 1037\u20131048 (2008).","journal-title":"J. Exp. Med."},{"key":"164_CR159","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.4049\/jimmunol.0903782","volume":"184","author":"JE McLaren","year":"2010","unstructured":"McLaren, J. E. et al. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. J. Immunol. 184, 5827\u20135834 (2010).","journal-title":"J. Immunol."},{"key":"164_CR160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1126\/science.274.5289.990","volume":"274","author":"AM Chinnaiyan","year":"1996","unstructured":"Chinnaiyan, A. M., O\u2019Rouke, K., Yu, G., Lyons, R. H. & Dixit, V. M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 2 (1996).","journal-title":"Science"},{"key":"164_CR161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cyto.2004.12.001","volume":"29","author":"YJ Kang","year":"2005","unstructured":"Kang, Y. J. et al. Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29, 229\u2013235 (2005).","journal-title":"Cytokine"},{"key":"164_CR162","first-page":"2","volume":"65","author":"SH Kim","year":"2001","unstructured":"Kim, S. H. et al. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Jpn Circ. J. 65, 2 (2001).","journal-title":"Jpn Circ. J."},{"key":"164_CR163","doi-asserted-by":"crossref","first-page":"19896","DOI":"10.1073\/pnas.1310838110","volume":"110","author":"J Sudhamsu","year":"2013","unstructured":"Sudhamsu, J. et al. Dimerization of LTbetaR by LTalpha1beta2 is necessary and sufficient for signal transduction. Proc. Natl Acad. Sci. USA 110, 19896\u201319901 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"164_CR164","doi-asserted-by":"crossref","first-page":"50523","DOI":"10.1074\/jbc.M309381200","volume":"278","author":"C Li","year":"2003","unstructured":"Li, C. et al. Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J. Biol. Chem. 278, 50523\u201350529 (2003).","journal-title":"J. Biol. Chem."},{"key":"164_CR165","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.4049\/jimmunol.149.12.3881","volume":"149","author":"CF Ware","year":"1992","unstructured":"Ware, C. F., Crowe, P. D., Grayson, M. H., Androlewicz, M. J. & Browning, J. L. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol. 149, 3881\u20133888 (1992).","journal-title":"J. Immunol."},{"key":"164_CR166","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-065X.2008.00629.x","volume":"223","author":"CF Ware","year":"2008","unstructured":"Ware, C. F. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol. Rev. 223, 186\u2013201 (2008).","journal-title":"Immunol. Rev."},{"key":"164_CR167","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/ATVBAHA.109.191395","volume":"30","author":"K Lotzer","year":"2010","unstructured":"Lotzer, K. et al. Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1\/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler. Thromb. Vasc. Biol. 30, 395\u2013402 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR168","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.immuni.2015.05.015","volume":"42","author":"D Hu","year":"2015","unstructured":"Hu, D. et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin beta receptors. Immunity 42, 1100\u20131115 (2015).","journal-title":"Immunity"},{"key":"164_CR169","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.atherosclerosis.2010.06.003","volume":"212","author":"AW Owens","year":"2010","unstructured":"Owens, A. W. et al. Circulating lymphotoxin beta receptor and atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 212, 601\u2013606 (2010).","journal-title":"Atherosclerosis"},{"key":"164_CR170","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1161\/CIRCRESAHA.116.305723","volume":"116","author":"M Grandoch","year":"2015","unstructured":"Grandoch, M. et al. Deficiency in lymphotoxin beta receptor protects from atherosclerosis in apoE-deficient mice. Circ. Res. 116, e57\u2013e68 (2015).","journal-title":"Circ. Res."},{"key":"164_CR171","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR172","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+\u2009T cell mediated injury in the heart. Circulation 116, 2062\u20132071 (2007).","journal-title":"Circulation"},{"key":"164_CR173","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.it.2016.11.007","volume":"38","author":"F Cheng","year":"2017","unstructured":"Cheng, F. & Loscalzo, J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 38, 77\u201378 (2017).","journal-title":"Trends Immunol."},{"key":"164_CR174","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"164_CR175","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"164_CR176","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood, T. G. et al. Smoldering myocarditis following immune checkpoint blockade. J. Immunother. Cancer 5, 91 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens, C. J. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLOS ONE 8, e53745 (2013).","journal-title":"PLOS ONE"},{"key":"164_CR178","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","volume":"23","author":"ME Roth","year":"2016","unstructured":"Roth, M. E., Muluneh, B., Jensen, B. C., Madamanchi, C. & Lee, C. B. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am. J. Ther. 23, e1925\u2013e1928 (2016).","journal-title":"Am. J. Ther."},{"key":"164_CR179","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E. & Schwartz, D. R. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J. Immunother. Cancer 3, 4 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR181","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H Laubli","year":"2015","unstructured":"Laubli, H. et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer 3, 11 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR182","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"164_CR183","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","volume":"9","author":"T Tadokoro","year":"2016","unstructured":"Tadokoro, T. et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ. Heart Fail. 9, e003514 (2016).","journal-title":"Circ. Heart Fail."},{"key":"164_CR184","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","volume":"99","author":"H Semper","year":"2016","unstructured":"Semper, H., Muehlberg, F., Schulz-Menger, J., Allewelt, M. & Grohe, C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 99, 117\u2013119 (2016).","journal-title":"Lung Cancer"},{"key":"164_CR185","doi-asserted-by":"crossref","first-page":"bcr2016216228","DOI":"10.1136\/bcr-2016-216228","volume":"2016","author":"R Gibson","year":"2016","unstructured":"Gibson, R., Delaune, J., Szady, A. & Markham, M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. 2016, bcr2016216228 (2016).","journal-title":"BMJ Case Rep."},{"key":"164_CR186","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","volume":"4","author":"VH Koelzer","year":"2016","unstructured":"Koelzer, V. H. et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J. Immunother. Cancer 4, 13 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"164_CR187","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/CMR.0000000000000251","volume":"26","author":"A Mehta","year":"2016","unstructured":"Mehta, A., Gupta, A., Hannallah, F., Koshy, T. & Reimold, S. Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 26, 319\u2013320 (2016).","journal-title":"Melanoma Res."},{"key":"164_CR188","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cvr\/cvx248","volume":"114","author":"PJH Kusters","year":"2018","unstructured":"Kusters, P. J. H., Lutgens, E. & Seijkens, T. T. P. Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovasc. Res. 114, 368\u2013377 (2018).","journal-title":"Cardiovasc. Res."},{"key":"164_CR189","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.immuni.2006.03.001","volume":"24","author":"JA Bluestone","year":"2006","unstructured":"Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233\u2013238 (2006).","journal-title":"Immunity"},{"key":"164_CR190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B. & Moslehi, J. J. Cardiovascular toxicities associated with cancer immunotherapies. Curr. Cardiol. Rep. 19, 21 (2017).","journal-title":"Curr. Cardiol. Rep."},{"key":"164_CR191","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.18632\/oncotarget.22579","volume":"8","author":"K Brustle","year":"2017","unstructured":"Brustle, K. & Heidecker, B. Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer. Oncotarget 8, 106165\u2013106166 (2017).","journal-title":"Oncotarget"},{"key":"164_CR192","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jjco\/hyx154","volume":"48","author":"K Tajiri","year":"2018","unstructured":"Tajiri, K., Aonuma, K. & Sekine, I. Immune checkpoint inhibitor-related myocarditis. Jpn J. Clin. Oncol. 48, 7\u201312 (2018).","journal-title":"Jpn J. Clin. Oncol."},{"key":"164_CR193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11739-017-1755-0","volume":"13","author":"E Raschi","year":"2018","unstructured":"Raschi, E., Diemberger, I., Cosmi, B. & De Ponti, F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Intern. Emerg. Med. 13, 1\u20139 (2018).","journal-title":"Intern. Emerg. Med."},{"key":"164_CR194","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","volume":"19","author":"MF Fransen","year":"2013","unstructured":"Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R. & Melief, C. J. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 19, 5381\u20135389 (2013).","journal-title":"Clin. Cancer Res."},{"key":"164_CR195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","volume":"13","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167\u2013179 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"164_CR196","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ehjci\/jev024","volume":"16","author":"P Lancellotti","year":"2015","unstructured":"Lancellotti, P. et al. EACVI\/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI\/HFA COT Registry)\u2014EURObservational Research Program of the European Society of Cardiology. Eur. Heart J. Cardiovasc. Imaging 16, 466\u2013470 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"164_CR197","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/physrev.00024.2005","volume":"86","author":"A Tedgui","year":"2006","unstructured":"Tedgui, A. & Mallat, Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86, 515\u2013581 (2006).","journal-title":"Physiol. Rev."},{"key":"164_CR198","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1172\/JCI61758","volume":"122","author":"EK Koltsova","year":"2012","unstructured":"Koltsova, E. K. et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J. Clin. Invest. 122, 3114\u20133126 (2012).","journal-title":"J. Clin. Invest."},{"issue":"Suppl","key":"164_CR199","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1194\/jlr.R800092-JLR200","volume":"50","author":"Z Mallat","year":"2009","unstructured":"Mallat, Z., Taleb, S., Ait-Oufella, H. & Tedgui, A. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res. 50 (Suppl), 364\u2013369 (2009).","journal-title":"J. Lipid Res."},{"key":"164_CR200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/cvr\/cvx196","volume":"114","author":"D Engelbertsen","year":"2017","unstructured":"Engelbertsen, D. et al. IL-1R and MyD88 signaling in CD4+ T cells promote Th17 immunity and atherosclerosis. Cardiovasc. Res. 114, 180\u2013187 (2017).","journal-title":"Cardiovasc. Res."},{"key":"164_CR201","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/ATVBAHA.117.310672","volume":"38","author":"M Adam","year":"2018","unstructured":"Adam, M. et al. Systemic upregulation of IL-10 (interleukin-10) using a nonimmunogenic vector reduces growth and rate of dissecting abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 38, 1796\u20131805 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.atherosclerosis.2006.09.032","volume":"193","author":"D Eefting","year":"2007","unstructured":"Eefting, D. et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis 193, 335\u2013342 (2007).","journal-title":"Atherosclerosis"},{"key":"164_CR203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.gene.6364343","volume":"8","author":"PS Monraats","year":"2007","unstructured":"Monraats, P. S. et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun. 8, 44\u201350 (2007).","journal-title":"Genes Immun."},{"key":"164_CR204","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI1216","volume":"101","author":"X Zhou","year":"1998","unstructured":"Zhou, X., Paulsson, G., Stemme, S. & Hansson, G. K. Hypercholesterolemia is associated with a T helper (Th) 1\/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101, 1717\u20131725 (1998).","journal-title":"J. Clin. Invest."},{"key":"164_CR205","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0002-9440(10)63471-2","volume":"163","author":"P Davenport","year":"2003","unstructured":"Davenport, P. & Tipping, P. G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117\u20131125 (2003).","journal-title":"Am. J. Pathol."},{"key":"164_CR206","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/hq0302.104905","volume":"22","author":"VL King","year":"2002","unstructured":"King, V. L., Szilvassy, S. J. & Daugherty, A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor\u2212\/\u2212 mice. Arterioscler. Thromb. Vasc. Biol. 22, 456\u2013461 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR207","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","volume":"183","author":"C Erbel","year":"2009","unstructured":"Erbel, C. et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J. Immunol. 183, 8167\u20138175 (2009).","journal-title":"J. Immunol."},{"key":"164_CR208","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.109.924886","volume":"121","author":"E Smith","year":"2010","unstructured":"Smith, E. et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121, 1746\u20131755 (2010).","journal-title":"Circulation"},{"key":"164_CR209","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCRESAHA.111.261784","volume":"110","author":"MJ Butcher","year":"2012","unstructured":"Butcher, M. J., Gjurich, B. N., Phillips, T. & Galkina, E. V. The IL-17A\/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ. Res. 110, 675\u2013687 (2012).","journal-title":"Circ. Res."},{"key":"164_CR210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","volume":"32","author":"K Danzaki","year":"2012","unstructured":"Danzaki, K. et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32, 273\u2013280 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"164_CR211","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.112.001347","volume":"127","author":"T Kyaw","year":"2013","unstructured":"Kyaw, T. et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127, 1028\u20131039 (2013).","journal-title":"Circulation"},{"key":"164_CR212","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2015.00171","volume":"6","author":"G Churlaud","year":"2015","unstructured":"Churlaud, G. et al. Human and mouse CD8+CD25+FOXP3+ regulatory T cells at steady state and during interleukin-2 therapy. Front. Immunol. 6, 171 (2015).","journal-title":"Front. Immunol."},{"key":"164_CR213","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00395-016-0589-7","volume":"111","author":"C Cochain","year":"2016","unstructured":"Cochain, C. & Zernecke, A. Protective and pathogenic roles of CD8+ T cells in atherosclerosis. Basic Res. Cardiol. 111, 71 (2016).","journal-title":"Basic Res. Cardiol."},{"key":"164_CR214","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery, P. et al. Impact of T cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the\u00a0ADJUST trial). Ann. Rheum. Dis. 69, 510\u2013516 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"164_CR215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-015-0671-9","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen, J. S. et al. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res. Ther. 17, 157 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"164_CR216","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery, P. et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann. Rheum. Dis. 74, 19\u201326 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"164_CR217","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens, R. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68, 1870\u20131877 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"164_CR218","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 3077\u20133087 (2010).","journal-title":"Arthritis Rheum."},{"key":"164_CR219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","volume":"10","author":"B Baban","year":"2015","unstructured":"Baban, B., Liu, J. Y., Qin, X., Weintraub, N. L. & Mozaffari, M. S. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLOS ONE 10, e0124059 (2015).","journal-title":"PLOS ONE"},{"key":"164_CR220","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","volume":"5","author":"E Lutgens","year":"1999","unstructured":"Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5, 1313\u20131316 (1999).","journal-title":"Nat. Med."},{"key":"164_CR221","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","volume":"394","author":"F Mach","year":"1998","unstructured":"Mach, F., Schonbeck, U., Sukhova, G. K., Atkinson, E. & Libby, P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200\u2013203 (1998).","journal-title":"Nature"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41569-019-0164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-019-0164-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-019-0164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:45:17Z","timestamp":1694627117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-019-0164-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":221,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1038\/s41569-019-0164-7","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"15 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}